RTW Venture Fund Limited (RTW)

Currency in -

Last close As at 06/02/2023


−0.01 (−0.69%)

Market capitalisation


RTW Venture Fund (RTWVF) was launched on 30 October 2019 and is focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The portfolio contains private as well as publicly listed companies. RTWVF’s performance is measured against an index of small-cap biotech stocks and the NASDAQ Biotechnology Index.

Equity Analyst

Melanie Jenner

Mel Jenner

Director, Investment Trusts

Share Price Performance


RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW). It has announced that on 7 December 2022 portfolio company Prometheus Biosciences (NASDAQ: RXDX, cap $4.9bn) reported positive data on two of its clinical trials. At 31 October 2022, which is the date of RTWVF’s last published NAV, Prometheus was its third-largest holding, making up c 7.5% of the fund. This company’s share price rose by 165.7% on 7 December and by a further 22.4% on 8 December (despite the announcement of an upsized $500m secondary offering). Prometheus is an example of RTW’s long-term, full life cycle investment approach, which supports companies ranging from newco formation to mid-stage venture to pre-initial public offering (IPO) and public markets.


Investment Companies

Vietnamese equities: Due a comeback?


IPO apocalypse


ESG, moving beyond the box tick

Investment Companies

The case for US capital markets

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free